AbbVie Inc. (4AB.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
As of 10:02AM CEST. Market open.
| Previous close | 157.48 |
| Open | 156.72 |
| Bid | 155.14 x N/A |
| Ask | 155.88 x N/A |
| Day's range | 156.44 - 156.78 |
| 52-week range | 118.80 - 168.92 |
| Volume | |
| Avg. volume | 718 |
| Market cap | 277B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 61.59 |
| EPS (TTM) | 2.54 |
| Earnings date | 26 Apr 2024 |
| Forward dividend & yield | 5.84 (3.71%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
ZacksWill Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Zacks4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
ZacksWhat's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
© 2024 Yahoo. All rights reserved.